Can-Fite BioPharma Ltd. (CANF) is a Biotechnology company in the Healthcare sector, currently trading at $3.05. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is CANF = $7 (+137.7% upside).
Valuation: CANF trades at a trailing Price-to-Earnings (P/E) of -794.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 13.73.
Financials: revenue is $408,212, -19%/yr average growth. Net income is $10M (loss), growing at -0.5%/yr. Net profit margin is -2426.7% (negative). Gross margin is 94.1% (-5.9 pp trend).
Balance sheet: total debt is $70,998 against $6M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 3.46 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $10M.
Analyst outlook: 3 / 4 analysts rate CANF as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 35/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
